Jan 14, 2025
FDA Clears Ariceum Therapeutics' 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma
Jan 10, 2025
David Schilansky Appointed Chief Financial Officer of Ariceum Therapeutics
Dec 11, 2024
Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225
Dec 05, 2024
Ariceum Therapeutics and Eckert & Ziegler Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
Jul 25, 2024
Ariceum Therapeutics Commences Phase 1 Clinical Trial in Patients with Recurrent Glioblastoma
Jun 10, 2024
Ariceum Therapeutics to Present Outstanding New Preclinical Data at the Society of Nuclear Medicine and Molecular Imaging Annual Meeting 2024
Apr 04, 2024
Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024
Mar 05, 2024
Ariceum Therapeutics announces opening of new state-of-the-art laboratory in Berlin providing infrastructure for radiopharmaceutical development activities
Feb 29, 2024
Ariceum Therapeutics Granted UK Authorisation to Conduct Phase I Clinical Study of its First-in-Class Iodine-123 Labelled PARP Inhibitor in Patients with Recurrent Glioblastoma
Jan 10, 2024
Ariceum Therapeutics files for UK Clinical Trial Authorisation (CTA) to test its First-in-Class Iodine-123 labelled PARP inhibitor in patients with recurrent glioblastoma